CERO Key Statistics, Chart & Performance
The current stock price of CERO is 0.0951 USD. In the past month the price decreased by -98.24%. In the past year, price decreased by -99.94%.
CERO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About CERO
Company Profile
CERo Therapeutics Holdings, Inc. is an immunotherapy company, which engages in development of engineered T cell therapeutics for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 8 full-time employees. The company went IPO on 2021-10-06. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what the Company refers to as Chimeric Engulfment Receptor T cells (CER-T). Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. The firm is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.
Company Info
CERO THERAPEUTICS HOLDINGS I
201 Haskins Way, Suite 230
South San Francisco CALIFORNIA US
Employees: 8
Phone: 6504072376
CERO THERAPEUTICS HOLDINGS I / CERO FAQ
What does CERO do?
CERo Therapeutics Holdings, Inc. is an immunotherapy company, which engages in development of engineered T cell therapeutics for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 8 full-time employees. The company went IPO on 2021-10-06. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what the Company refers to as Chimeric Engulfment Receptor T cells (CER-T). Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. The firm is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.
Can you provide the latest stock price for CERO THERAPEUTICS HOLDINGS I?
The current stock price of CERO is 0.0951 USD. The price decreased by -94.69% in the last trading session.
What is the dividend status of CERO THERAPEUTICS HOLDINGS I?
CERO does not pay a dividend.
What is the ChartMill rating of CERO THERAPEUTICS HOLDINGS I stock?
CERO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What do analysts say about CERO THERAPEUTICS HOLDINGS I (CERO) stock?
8 analysts have analysed CERO and the average price target is 22.95 USD. This implies a price increase of 24032.49% is expected in the next year compared to the current price of 0.0951.
Can you provide the sector and industry classification for CERO THERAPEUTICS HOLDINGS I?
CERO THERAPEUTICS HOLDINGS I (CERO) operates in the Health Care sector and the Biotechnology industry.
CERO Technical Analysis
CERO Financial Highlights
Over the last trailing twelve months CERO reported a non-GAAP Earnings per Share(EPS) of -223.77. The EPS increased by 63.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -675.76% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CERO Forecast & Estimates
8 analysts have analysed CERO and the average price target is 22.95 USD. This implies a price increase of 24032.49% is expected in the next year compared to the current price of 0.0951.